[go: up one dir, main page]

DK4360713T3 - Quinazolinderivater som antitumormidler - Google Patents

Quinazolinderivater som antitumormidler Download PDF

Info

Publication number
DK4360713T3
DK4360713T3 DK23219357.3T DK23219357T DK4360713T3 DK 4360713 T3 DK4360713 T3 DK 4360713T3 DK 23219357 T DK23219357 T DK 23219357T DK 4360713 T3 DK4360713 T3 DK 4360713T3
Authority
DK
Denmark
Prior art keywords
antitumor agents
quinazoline derivatives
quinazoline
derivatives
antitumor
Prior art date
Application number
DK23219357.3T
Other languages
English (en)
Inventor
Ding Zhou
Ziqiang Cheng
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK4360713T3 publication Critical patent/DK4360713T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK23219357.3T 2018-09-18 2019-09-17 Quinazolinderivater som antitumormidler DK4360713T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018106098 2018-09-18
CN2019091078 2019-06-13
EP19862146.8A EP3853220B1 (en) 2018-09-18 2019-09-17 Quinazoline derivatives as antitumor agents

Publications (1)

Publication Number Publication Date
DK4360713T3 true DK4360713T3 (da) 2025-01-06

Family

ID=69888359

Family Applications (2)

Application Number Title Priority Date Filing Date
DK23219357.3T DK4360713T3 (da) 2018-09-18 2019-09-17 Quinazolinderivater som antitumormidler
DK19862146.8T DK3853220T3 (da) 2018-09-18 2019-09-17 Quinazolinderivater som antitumormidler

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19862146.8T DK3853220T3 (da) 2018-09-18 2019-09-17 Quinazolinderivater som antitumormidler

Country Status (18)

Country Link
US (2) US11723908B2 (da)
EP (3) EP3853220B1 (da)
JP (2) JP7546550B2 (da)
CN (2) CN112654612A (da)
AU (2) AU2019341273B2 (da)
CA (1) CA3099776A1 (da)
DK (2) DK4360713T3 (da)
ES (2) ES2971927T3 (da)
FI (2) FI3853220T3 (da)
HR (2) HRP20240293T1 (da)
HU (2) HUE069764T2 (da)
LT (2) LT4360713T (da)
PL (2) PL3853220T3 (da)
PT (2) PT3853220T (da)
RS (2) RS66314B1 (da)
SI (2) SI3853220T1 (da)
SM (1) SMT202400524T1 (da)
WO (1) WO2020057511A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3778589B1 (en) * 2018-04-09 2022-05-11 Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. 5-substituted difluoropiperidine compound capable of passing through blood-brain barrier
CN110357858B (zh) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
EP3853220B1 (en) * 2018-09-18 2024-01-03 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents
CN111377850B (zh) * 2018-12-31 2022-10-18 艾琪康医药科技（上海）有限公司 一种手性n-取代-3,3-二氟-4-羟基哌啶衍生物及其制备方法
WO2021209039A1 (zh) * 2020-04-17 2021-10-21 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
CN113527215B (zh) * 2020-04-17 2023-12-05 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、制备方法及其应用
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
EP4293016A4 (en) * 2021-03-19 2024-08-07 Beijing Scitech-MQ Pharmaceuticals Limited Quinazoline-based compound, composition, and application of quinazoline-based compound
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
WO2022271613A1 (en) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
WO2022271749A1 (en) * 2021-06-22 2022-12-29 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
US20240382483A1 (en) * 2021-06-22 2024-11-21 Blueprint Medicines Corporation Heterocyclic egfr inhibitors for use in the treatment of cancer
US20240300946A1 (en) * 2021-06-22 2024-09-12 Blueprint Medicines Corporation Egfr inhibitors
CN115894455B (zh) * 2021-09-30 2024-04-19 北京赛特明强医药科技有限公司 一种喹唑啉类化合物、组合物及其应用
JP2024539212A (ja) * 2021-10-20 2024-10-28 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト キナゾリン誘導体の結晶形態、調製、組成物およびその使用
CN116478129B (zh) * 2022-01-21 2025-01-07 深圳默元生物科技有限公司 喹啉化合物及其用途
EP4493184A1 (en) * 2022-03-14 2025-01-22 Huyabio International, LLC Blood-brain barrier crossing mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
CN118715216A (zh) * 2022-03-28 2024-09-27 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
CN115650977A (zh) * 2022-10-09 2023-01-31 广东润兴生物科技有限公司 一种妥卡替尼的合成方法
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲（江蘇）醫藥股份有限公司 喹唑啉ＥｒｂＢ抑制劑的藥物形式
WO2024249642A1 (en) * 2023-06-02 2024-12-05 Acerand Therapeutics (Hong Kong) Limited Egfr inhibitors
TW202530231A (zh) * 2023-09-27 2025-08-01 大陸商江蘇恒瑞醫藥股份有限公司 喹唑啉衍生物的可藥用鹽、其結晶形式及用途
WO2025195333A1 (en) 2024-03-19 2025-09-25 F. Hoffmann-La Roche Ag Pharmaceutical formulation of erbb2 inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587657D1 (de) 1984-01-30 1993-12-23 Imp Cancer Res Tech Verbesserungen an wachstumsfaktoren.
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
WO1991005264A1 (en) 1989-09-29 1991-04-18 Oncogenetics Partners Detection and quantification of neu related proteins in the biological fluids of humans
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
PT880508E (pt) 1996-02-13 2003-07-31 Astrazeneca Ab Derivados de quinazolina como inibidores de vegf
IL125954A (en) 1996-03-05 2003-06-24 Zeneca Ltd Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2001092224A1 (en) 2000-05-31 2001-12-06 Astrazeneca Ab Indole derivatives with vascular damaging activity
CN1330640C (zh) 2000-06-22 2007-08-08 辉瑞产品公司 用于治疗异常细胞生长的取代的双环衍生物
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
CN100343238C (zh) * 2001-11-03 2007-10-17 阿斯特拉曾尼卡有限公司 用作抗肿瘤药物的喹唑啉衍生物
US7235537B2 (en) 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
AU2003250844A1 (en) 2002-06-24 2004-01-06 Fagerdala Deutschland Gmbh Method for producing parts from high-grade lignocellulose fiber-filled thermoplastics
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
KR101028952B1 (ko) 2003-08-14 2011-04-12 어레이 바이오파마 인크. 수용체 티로신 키나아제 억제제로서의 퀴나졸린 유사체
CN101356171A (zh) * 2005-11-15 2009-01-28 阿雷生物药品公司 作为erbbi型受体酪氨酸激酶抑制剂用于治疗增殖性疾病的n4-苯基-喹唑啉-4-胺衍生物和相关化合物
CN101611041A (zh) * 2006-12-12 2009-12-23 武田药品工业株式会社 稠合杂环化合物
US10828305B2 (en) 2016-03-01 2020-11-10 Shanghai Pharmaceuticals Holding Co., Ltd. Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
EP3516071B1 (en) * 2016-09-22 2021-02-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of lung cancer
EP3677583A4 (en) 2017-09-01 2021-07-21 Shanghai Pharmaceuticals Holding Co., Ltd. NITROGENOUS HETEROCYCLIC COMPOUND, METHOD OF PREPARATION, INTERMEDIATE, COMPOSITION AND APPLICATION
CN111630046B (zh) * 2017-12-19 2023-01-10 成都金瑞基业生物科技有限公司 喹唑啉衍生物及其应用
CN112105618B (zh) * 2018-05-08 2022-05-31 南京明德新药研发有限公司 作为选择性HER2抑制剂的吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
TWI811358B (zh) * 2018-05-08 2023-08-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑
EP3853220B1 (en) * 2018-09-18 2024-01-03 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents

Also Published As

Publication number Publication date
JP7546550B2 (ja) 2024-09-06
CN112654612A (zh) 2021-04-13
HRP20241743T1 (hr) 2025-02-28
SI3853220T1 (sl) 2024-04-30
JP2022501338A (ja) 2022-01-06
EP4523755A3 (en) 2025-06-11
EP4360713A2 (en) 2024-05-01
HUE069764T2 (hu) 2025-04-28
RS65413B1 (sr) 2024-05-31
US20230293533A1 (en) 2023-09-21
EP3853220B1 (en) 2024-01-03
EP4360713A3 (en) 2024-05-22
SMT202400524T1 (it) 2025-01-14
EP4360713B1 (en) 2024-10-30
EP4523755A2 (en) 2025-03-19
AU2019341273A1 (en) 2020-11-19
US11723908B2 (en) 2023-08-15
AU2024204847A1 (en) 2024-08-01
ES2971927T3 (es) 2024-06-10
HUE065578T2 (hu) 2024-06-28
DK3853220T3 (da) 2024-03-04
PT3853220T (pt) 2024-02-22
LT4360713T (lt) 2025-01-10
WO2020057511A1 (en) 2020-03-26
SI4360713T1 (sl) 2025-02-28
ES3007082T3 (en) 2025-03-19
PL4360713T3 (pl) 2025-06-23
PT4360713T (pt) 2025-01-07
FI4360713T3 (fi) 2024-12-27
JP2024164018A (ja) 2024-11-26
FI3853220T3 (fi) 2024-02-22
LT3853220T (lt) 2024-03-12
EP3853220A1 (en) 2021-07-28
KR20210061329A (ko) 2021-05-27
AU2019341273B2 (en) 2024-09-26
CN118255772A (zh) 2024-06-28
CA3099776A1 (en) 2020-03-26
PL3853220T3 (pl) 2024-09-02
RS66314B1 (sr) 2025-01-31
HRP20240293T1 (hr) 2024-05-24
EP3853220A4 (en) 2022-06-22
US20210386742A1 (en) 2021-12-16

Similar Documents

Publication Publication Date Title
DK3853220T3 (da) Quinazolinderivater som antitumormidler
PT3958977T (pt) Derivados de camptotecina
EP3813864A4 (en) Antitumor antagonists
IL292161A (en) New methylquinazolinone derivatives
DK3656769T3 (da) Aryl-phosphor-oxygen-forbindelse som egfr-kinase-inhibitor
DK3510034T3 (da) Substituerede imidazo-quinoliner som nlrp3-modulatorer
DK3768674T3 (da) Aminopyrimidinderivater som ctps1-hæmmere
PL3897842T3 (pl) Pochodne bicykliczne
PL4013751T3 (pl) Pochodne 2-hydroksycykloalkano-1-karbamoilu
LT3830085T (lt) Deuterinti lanifibranoro dariniai
DK3642202T3 (da) Dihydro-pyrrolo-pyridin-derivater
ME03467B (me) Antitumorska jedinjenja
DK3464309T3 (da) Phosphoramidatnukleosidderivater som anticancermidler
DK3768669T3 (da) Piperazinazaspiroderivater
EP4077334C0 (en) FUROINDAZOLE DERIVATIVES
EP4021904C0 (en) ALPHA-D-GALACTOPYRANOSIDE DERIVATIVES
EP3718545A4 (en) ANTI-TUMOR AGENT
DK3823971T3 (da) Substituerede triazol-quinoxalin-derivater
DK3796975T3 (da) Sulfonylaminobenzamidderivater
DK4056557T3 (da) Benzazepinderivater nyttige som medikamenter
DK3894410T3 (da) Substituerede xanthinderivater
DK3770162T3 (da) Dihydrochromenderivater
EP3976601C0 (en) MICROBIOCIDAL DERIVATIVES
EP3782983A4 (en) ISOINDOLE DERIVATIVE
EP3595647A4 (en) ARYL-PIPERIDINE DERIVATIVES